AVROBIO AVRO announced positive interim data from a phase I/II study, which is evaluating the safety and efficacy of AVR-RD-04, an investigational gene-therapyfor cystinosis, a rare but ...

Avrobio stock is surging on upbeat clinical drug data for its gene therapy AVR-RD-01 in patients with Fabry Disease BREAKING NEWS: Dow Logs Longest Win Streak Since 2017; SPX, Nasdaq Cool ...